Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about?

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_752C7C97D18E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about?
Périodique
Swiss Medical Weekly
Auteur(s)
Faeh D., Chiolero A., Paccaud F.
ISSN
1424-7860 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
136
Numéro
47-48
Pages
745-756
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD is causally related to "classical" risk factors such as elevated blood pressure, cholesterol, or glucose level and smoking. A causal role in the development of CVD is also suggested for numerous other factors, including an elevated plasma homocysteine concentration. Variation of homocysteinaemia is mainly due to genetic mutations and/or vitamin deficiency. The homocysteine concentration can be lowered with folate. Vitamin supplementation has thus been proposed in individuals with hyperhomocysteinaemia in order to reduce their CVD risk. On the other hand, population-based studies show little or no association between moderate hyperhomocysteinaemia and CVD risk. Nor has any randomised clinical trial clearly proven the efficacy of lowering the homocysteine concentration as a means of lowering the incidence of CVD. Hence at present it is inappropriate to recommend screening and treatment of hyperhomocysteinaemia in asymptomatic persons with or without other CVD risk. Until new evidence is available, clinicians should focus on better control of the "classical" risk factors for CVD.
Mots-clé
Biological Markers/blood, Cardiovascular Diseases/etiology, Cardiovascular Diseases/prevention & control, Evidence-Based Medicine, Homocysteine/blood, Humans, Hyperhomocysteinemia/complications, Mass Screening, Randomized Controlled Trials as Topic, Risk Factors, Uncertainty, Vitamin B Complex/therapeutic use
Pubmed
Web of science
Création de la notice
04/03/2008 15:58
Dernière modification de la notice
11/06/2018 12:28
Données d'usage